Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

Even though randomized controlled clinical trials demonstrated improved survival by adjuvant trastuzumab treatment of HER2-positive breast cancer patients, data on its effect in clinical routine are scarce. This study evaluated the use and efficacy of trastuzumab in routine treatment of HER2-positiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Inwald, E. C., Ortmann, O., Zeman, F., Koller, M., Hofstädter, F., Gerstenhauer, M., Klinkhammer-Schalke, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977430/
https://www.ncbi.nlm.nih.gov/pubmed/24779005
http://dx.doi.org/10.1155/2014/137304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977430/
https://www.ncbi.nlm.nih.gov/pubmed/24779005
http://dx.doi.org/10.1155/2014/137304

Ejemplares similares